Respiratory toxicology studies are an important component of preclinical drug development, particularly when a therapeutic is intended to treat diseases of the lungs and airways or is administered directly to the respiratory tract.
Before a new respiratory therapeutic progresses into clinical development, researchers need to understand not only whether the candidate produces the desired pharmacological effect, but also whether it has an appropriate safety profile.
Respiratory toxicology focuses on identifying and characterising potentially harmful effects associated with exposure to a drug or therapeutic candidate. Depending on the compound and development programme, this can include investigation of effects on the lungs, airways, respiratory function and other relevant biological systems.
For pharmaceutical and biotechnology companies developing treatments for asthma, COPD, pulmonary fibrosis, respiratory infections and other pulmonary diseases, integrating respiratory toxicology with respiratory pharmacology, pharmacokinetics, pharmacodynamics and disease-model research can provide a more complete understanding of a candidate’s development potential.
What Is Respiratory Toxicology?
Respiratory toxicology is the study of potentially harmful effects of chemical or biological substances on the respiratory system.
The respiratory system can be particularly important during preclinical safety assessment because it may represent either the intended site of drug action or a potential route of exposure.
Respiratory toxicology studies may investigate potential effects involving:
- The lungs
- Airways
- Pulmonary tissue
- Respiratory function
- Inflammatory responses
- Cellular changes
- Tissue pathology
- Local tolerability
- Systemic exposure
- Other organs potentially affected by treatment
The precise approach depends on the therapeutic modality, route of administration, intended indication and stage of development.
For a systemic drug being developed for a respiratory indication, respiratory findings may form one part of a wider toxicology programme. For an inhaled therapy, however, local pulmonary exposure can be particularly important because the lungs may receive relatively direct exposure to the candidate.
Why Are Respiratory Toxicology Studies Important?
Respiratory drug development requires evidence of both therapeutic activity and safety.
A candidate may demonstrate promising efficacy in a respiratory disease model, but this does not necessarily mean that it is suitable for further development.
Researchers need to understand whether the observed therapeutic activity can be achieved at exposures that have an acceptable safety profile.
Respiratory toxicology studies can therefore help answer questions such as:
- Does the candidate cause adverse effects in the respiratory system?
- Are observed effects related to dose or exposure?
- Does repeated exposure result in changes within pulmonary tissue?
- Is there evidence of local respiratory irritation or inflammation?
- Are there systemic effects associated with treatment?
- Is there a relationship between exposure and toxicity?
- Does the candidate have an appropriate safety margin for further development?
These questions become increasingly important as a respiratory drug programme progresses from discovery into more advanced preclinical development.
Pulmonary Toxicology and Respiratory Drug Development
Pulmonary toxicology is particularly relevant to therapies that interact directly with the respiratory tract.
The lungs have a large surface area and are exposed to substances entering through inhalation. This creates opportunities for targeted drug delivery but also means that local exposure needs to be considered carefully.
For inhaled respiratory therapeutics, researchers may need to understand the relationship between:
Administration → Pulmonary exposure → Pharmacological activity → Local effects → Systemic exposure
This can be investigated alongside pharmacokinetic and pharmacodynamic studies.
Understanding this relationship can help researchers distinguish between a desired pharmacological effect and an undesirable toxicological response.
Respiratory Toxicology for Inhaled Drug Development
Inhaled drug development presents specific preclinical considerations.
Unlike many systemically administered medicines, inhaled therapies are designed to reach the respiratory tract directly. The intended therapeutic effect may therefore depend on achieving sufficient local pulmonary exposure.
At the same time, high local exposure could potentially produce unwanted effects.
Preclinical research for inhaled therapies can therefore consider:
- Pulmonary drug deposition
- Local exposure
- Systemic exposure
- Dose-response relationships
- Respiratory pharmacology
- Local tolerability
- Pulmonary inflammation
- Tissue changes
- Pharmacodynamic biomarkers
- Overall safety
These investigations can be integrated into the broader respiratory drug development programme.
Respiratory Safety Studies
Respiratory safety studies can provide information about how a drug candidate affects the respiratory system under defined experimental conditions.
Depending on the research programme, endpoints may include assessments of:
- Respiratory function
- Lung inflammation
- Histopathology
- Cellular responses
- Pulmonary biomarkers
- Tissue morphology
- Airway responses
- Clinical observations
- Systemic safety parameters
The choice of endpoints should be driven by the biological mechanism, route of administration and intended therapeutic application.
For example, a drug targeting airway inflammation may require different safety considerations from a therapy designed to modify pulmonary fibrosis.
This is why respiratory toxicology should be considered within the context of the overall pharmacological and biological profile of the candidate.
Dose and Exposure in Respiratory Toxicology
Dose is a fundamental consideration in preclinical toxicology.
Researchers need to understand how different exposure levels influence both pharmacological activity and potential adverse effects.
Dose-response information can help establish whether an observed finding:
- Occurs only at high exposure
- Appears at therapeutically relevant exposure
- Increases with increasing dose
- Is reversible
- Is associated with systemic exposure
- Is associated with local pulmonary exposure
This can be particularly important when developing inhaled therapies, where local and systemic exposure may not follow exactly the same pattern.
Combining toxicology data with pharmacokinetic and pharmacodynamic studies can therefore provide a more useful interpretation of safety findings.
Respiratory Toxicology and Pharmacokinetics
Pharmacokinetics examines how a therapeutic candidate behaves within the body.
In respiratory drug development, PK data can provide important context for toxicology findings by helping researchers understand the exposure associated with observed effects.
Important pharmacokinetic parameters can include factors such as:
- Drug concentration
- Exposure over time
- Absorption
- Distribution
- Metabolism
- Elimination
- Local versus systemic exposure
When PK data are considered alongside toxicology findings, researchers can begin to establish an exposure-response relationship.
This can help distinguish between toxicity associated with high exposure and effects occurring closer to anticipated therapeutic exposure.
Respiratory Toxicology and Pharmacodynamics
Pharmacodynamics examines the biological effects produced by a therapeutic candidate.
Combining pharmacodynamic endpoints with toxicology can help researchers understand the therapeutic window of a candidate.
For example, researchers may investigate whether increasing exposure produces:
- Greater target engagement
- Increased pharmacological activity
- A plateau in therapeutic response
- Additional unwanted biological effects
This type of analysis can contribute to understanding the relationship between pharmacological efficacy and safety.
For respiratory therapeutics, appropriate pharmacodynamic biomarkers can also support translational respiratory research by providing measurable indicators of biological activity.
The Role of Respiratory Disease Models
Respiratory disease models are primarily used to investigate disease biology and therapeutic efficacy, but they can also contribute to understanding the overall biological profile of a candidate.
Models may be used in research involving:
- Asthma
- COPD
- Pulmonary fibrosis
- Acute lung injury
- Respiratory inflammation
- Viral respiratory disease
- Airway hyperresponsiveness
- Other pulmonary disorders
The purpose of using a disease model is different from conducting a dedicated toxicology study. Disease models are generally intended to reproduce relevant aspects of disease biology and evaluate therapeutic effects, while toxicology studies focus specifically on safety.
However, integrating findings across these research areas can provide a more complete preclinical picture.
Respiratory Toxicology in Preclinical Respiratory Research
Preclinical respiratory research often involves multiple complementary study types.
A respiratory drug development programme may include:
Respiratory Pharmacology
Investigates how the candidate interacts with biological pathways relevant to respiratory disease.
Disease Models
Assesses therapeutic activity in models representing relevant aspects of asthma, COPD, fibrosis, infection or other respiratory diseases.
Pharmacokinetics
Characterises exposure and the behaviour of the drug within the body.
Pharmacodynamics
Measures biological responses associated with treatment.
Biomarkers
Provides additional information about mechanism, target engagement and treatment response.
Respiratory Toxicology
Investigates potential adverse effects and contributes to the overall safety assessment.
Considering these elements together can create a more integrated preclinical development strategy.
Respiratory Toxicology for Different Therapeutic Areas
The requirements of respiratory toxicology research can vary significantly depending on the indication.
Asthma Drug Development
Asthma therapies may target inflammation, airway hyperresponsiveness, bronchoconstriction or other biological pathways.
Preclinical research may therefore combine respiratory pharmacology and asthma disease models with appropriate safety investigations.
COPD Drug Development
COPD research can involve chronic inflammatory processes and structural changes within the lungs.
Safety assessment may therefore form part of a broader programme investigating both therapeutic effects and potential pulmonary consequences of repeated exposure.
Pulmonary Fibrosis
Pulmonary fibrosis therapeutics are intended to influence pathways involved in abnormal tissue remodelling and fibrosis.
Preclinical respiratory research may investigate both anti-fibrotic activity and potential effects on pulmonary tissue.
Respiratory Infection
Antiviral and other anti-infective respiratory therapies may be evaluated using appropriate infection or challenge models.
Researchers may investigate therapeutic activity alongside safety and tolerability to establish an overall preclinical profile.
Local and Systemic Safety
One of the important considerations in respiratory drug development is distinguishing local pulmonary effects from systemic effects.
For an inhaled therapy, a compound may achieve substantial exposure within the lungs while producing comparatively different systemic exposure.
This creates a need to consider both:
Local pulmonary safety
and
Systemic safety
The balance between these factors can influence how a candidate is evaluated during preclinical development.
Appropriate study design can help researchers understand where exposure occurs and whether observed findings are associated with local or systemic drug exposure.
Translational Respiratory Research
The ultimate objective of preclinical research is to generate evidence that can inform decisions about human development.
This makes translational respiratory research an important consideration when designing respiratory toxicology and pharmacology programmes.
Where appropriate, researchers can select biomarkers, endpoints and experimental approaches that provide connections between preclinical research and potential clinical measurements.
A translational approach can help create continuity between:
Respiratory drug discovery → Preclinical respiratory research → Toxicology → IND-enabling development → Clinical research
This does not eliminate the uncertainty associated with translating findings between experimental models and humans, but it can help ensure that preclinical studies are designed around clinically relevant development questions.
Working With a Respiratory CRO
Pharmaceutical and biotechnology companies may use a specialist respiratory CRO to support preclinical research and respiratory drug development.
When evaluating a respiratory CRO, companies may consider expertise across several complementary areas, including:
- Respiratory pharmacology
- Respiratory disease models
- In vivo respiratory studies
- Pulmonary inflammation
- Respiratory biomarkers
- Pharmacokinetics
- Pharmacodynamics
- Respiratory toxicology
- Inhaled drug development
- Translational respiratory research
- Preclinical efficacy testing
A CRO with experience across multiple areas of respiratory preclinical research may be able to support a more integrated development programme.
How Respiratory Toxicology Fits Into the Drug Development Process
Respiratory toxicology does not exist in isolation.
A typical respiratory drug development programme can involve several stages:
1. Target Identification
Researchers identify and investigate a biological target associated with respiratory disease.
2. Respiratory Drug Discovery
Potential therapeutic candidates are identified and characterised.
3. Respiratory Pharmacology
Candidates are assessed for biological activity and mechanism.
4. Preclinical Disease Models
Promising candidates are investigated in appropriate respiratory disease models.
5. PK/PD Studies
Exposure and pharmacological response are characterised.
6. Safety and Toxicology
Potential adverse effects are investigated as the candidate progresses through development.
7. IND-Enabling Development
The appropriate nonclinical package is assembled to support progression towards clinical research.
Each programme is different, and the specific studies required depend on the therapeutic candidate and development pathway.
The Importance of Integrated Respiratory Preclinical Research
Successful respiratory drug development requires more than demonstrating that a candidate works in an experimental model.
Researchers need to understand why it works, where it acts, what exposure is required, how the biological response can be measured and whether the candidate has an appropriate safety profile.
Respiratory toxicology studies are an important part of answering those questions.
When integrated with respiratory pharmacology, disease models, biomarkers, pharmacokinetics and pharmacodynamics, respiratory toxicology can contribute to a comprehensive preclinical evidence base.
For companies developing new respiratory therapeutics, this integrated approach can help identify potential development challenges earlier and support better-informed decisions as programmes move towards clinical development.
Conclusion
Respiratory toxicology studies play an important role in the development of new pulmonary and respiratory therapeutics.
By investigating potential effects on the lungs, airways and wider biological systems, respiratory toxicology can complement efficacy, pharmacology, PK/PD and biomarker research.
This is particularly important for inhaled drug development, where local pulmonary exposure can be a central part of the therapeutic strategy.
Whether a programme is focused on asthma, COPD, pulmonary fibrosis, respiratory infection, acute lung injury or another respiratory indication, appropriate preclinical safety research can help establish a clearer understanding of the relationship between dose, exposure, pharmacological activity and safety.
Ultimately, integrating respiratory toxicology with broader respiratory preclinical research and translational respiratory research can help create a stronger evidence base for progressing promising respiratory drug candidates through development and towards clinical research.